Document is current
Any future updates will be listed below
-
Authors
Patil, S. B.
Tamirat, M.
Khazhidinov, K.
Ardizzoni, E.
Atger, M.
Austin, A.
Baudin, E.
Bekhit, M.
Bektasov, S.
Berikova, E.
Bonnet, M.
Caboclo, R.
Chaudhry, M.
Chavan, V.
Cloez, S.
Coit, J.
Coutisson, S.
Dakenova, Z.
De Jong, B. C.
Delifer, C.
Demaisons, S.
Do, J. M.
Dos Santos Tozzi, D.
Ducher, V.
Ferlazzo, G.
Gouillou, M.
Khan, U.
Kunda, M.
Lachenal, N.
LaHood, A. N.
Lecca, L.
Mazmanian, M.
McIlleron, H.
Moreau, M.
Moschioni, M.
Nahid, P.
Osso, E.
Oyewusi, L.
Panda, S.
Pâquet, A.
Thuong Huu, P.
Pichon, L.
Rich, M. L.
Rupasinghe, P.
Salahuddin, N.
Sanchez Garavito, E.
Seung, K. J.
Velásquez, G. E.
Vallet, M.
Varaine, F.
Yuya-Septoh, F. J.
Mitnick, C. D.
Guglielmetti, L.
-
Funding
Funding for this research was provided by:
Unitaid (SPHQ15-LOA-045)
Médecins Sans Frontières
Partners In Health
- License Information
-
More Information
Article History
Received: 30 June 2023
Accepted: 4 October 2023
First Online: 30 November 2023
Declarations
:
: Ethics approval for the study protocol and informed consent materials was granted before the study start from the following IRBs: Médecins sans Frontières Ethics Review Board, Harvard Medical School Institutional Review Board, Interactive Research and Development Institutional Review Board, Institute of Tropical Medicine Institutional Review Board, and IRBs/Ethics Committees in all countries in which the study is implemented. Any amendments to the protocol or consent materials are reviewed and approved by central IRBs (MSF, HMS) before they are submitted to local authorities and local IRBs for approval.
: Not applicable.
: The endTB Consortium coordinated donations of delamanid (Otsuka Pharmaceutical) and bedaquiline (Janssen) to be used for treatment by some of the patients included in the endTB Observational Study.Authors report the following potential conflicts of interest: none other than the donations disclosed above.
